TABLE 1.
All patients (N = 108) | Low‐grade (N = 54) | High‐grade (N = 54) | P‐value a | ||
---|---|---|---|---|---|
Variable | N (%) | N (%) | N (%) | ||
Age (y) | Median (range) | 30.0 (4‐63) | 27.0 (4‐54) | 35.5 (8‐63) | .001 |
Sex | Female | 41 (38.0%) | 16 (29.6%) | 25 (46.3%) | .074 |
Male | 67 (62.0%) | 38 (70.4%) | 29 (53.7%) | ||
Location | C | 40 (37.0%) | 21 (38.9%) | 19 (35.2%) | .896 |
C‐T | 16 (14.8%) | 8 (14.8%) | 8 (14.8%) | ||
T | 44 (40.8%) | 22 (40.7%) | 22 (40.7%) | ||
T‐L | 8 (7.4%) | 3 (5.6%) | 5 (9.3%) | ||
Segment length | Average | 3.91 | 3.78 | 4.04 | .434 |
Resection | GTR | 58 (53.7%) | 35 (64.8%) | 23 (42.6%) | .054 |
STR | 18 (16.7%) | 8 (14.8%) | 10 (18.5%) | ||
OB | 32 (29.6%) | 11 (20.4%) | 21 (38.9%) | ||
Presurgery MMS | 1 | 4 (3.7%) | 3 (5.7%) | 1 (1.9%) | <.001 |
2 | 50 (46.7%) | 37 (69.8%) | 13 (24.1%) | ||
3 | 36 (33.6%) | 10 (18.9%) | 26 (48.1%) | ||
4 | 17 (15.9%) | 3 (5.7%) | 14 (25.9%) | ||
NA | 1 | 1 | 0 | ||
Postsurgery MMS | 1 | 5 (4.7%) | 4 (7.5%) | 1 (1.9%) | <.001 |
2 | 39 (36.4%) | 31 (58.5%) | 8 (14.8%) | ||
3 | 44 (41.1%) | 16 (30.2%) | 28 (51.9%) | ||
4 | 19 (17.8%) | 2 (3.8%) | 17 (31.5%) | ||
NA | 1 | 1 | 0 | ||
Radiotherapy | Yes | 62 (67.4%) | 32 (66.7%) | 30 (68.2%) | .877 |
No | 30 (32.6%) | 16 (33.3%) | 14 (31.8%) | ||
NA | 16 | 6 | 10 | ||
Chemotherapy | Yes | 27 (29.3%) | 8 (16.7%) | 19 (43.2%) | .005 |
No | 65 (70.7%) | 40 (83.3%) | 25 (56.8%) | ||
NA | 16 | 6 | 10 | ||
Ki‐67 | <10% | 53 (51.0%) | 42 (82.4%) | 11 (20.8%) | <.001 |
≥10% | 51 (49.0%) | 9 (19.6%) | 42 (79.2%) | ||
NA | 4 | 3 | 1 | ||
H3 K27M | Negative | 62 (62.0%) | — | 15 (28.3%) | — |
Positive | 38 (38.0%) | — | 38 (71.7%) | ||
NA | 8 b | 7 | 1 |
Note: Significance of bold values P < .05.
Abbreviations: C, cervical; C‐T, cervicothoracic; GTR, gross total resection; MMS, Modified McCormick Scale; NA, not available; OB, open biopsy; STR, subtotal resection; T, thoracic; T‐L, thoracolumbar.
P‐values for the t test or Chi‐squared test or Mann‐Whitney U test used to compare low‐grade and high‐grade tumors.
Patients before 2016 without data on H3 K27M mutation and without adequate tissue sample available for added immunohistochemistry, including 2, 5, and 1 patient with grade I, II, and III tumors, respectively.